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Abstract: We report an analysis of in vitro and in vivo drug release from an in situ   formulation 
consisting of triamcinolone acetonide (TR) and poly(d,l-lactide-co-glycolide) (PLGA) and the 
additives glycofurol (GL) and hydroxyapatite nanoparticles (HA). We found that these additives 
enhanced drug release rate. We used the Taguchi method to predict optimum formulation variables 
to minimize the initial burst. This method decreased the burst rate from 8% to 1.3%. PLGA-HA 
acted as a strong buffer, thereby preventing tissue inflammation at the injection site caused by 
the acidic degradation products of PLGA. Characterization of the optimized   formulation by a 
variety of techniques, including scanning electron microscopy, X-ray   diffraction, differential 
scanning calorimetry, and Fourier transform near infrared spectroscopy, revealed that the crys-
talline structure of TR was converted to an amorphous form. Therefore, this hydrophobic agent 
can serve as an additive to modify drug release rates. Data generated by in vitro and in vivo 
experiments were in good agreement.
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Introduction
Injectable drug delivery systems have improved significantly.1–3 These improvements 
make them easier to use, enable targeted delivery,4–6 optimize delivery periods, mini-
mize side effects by reducing drug dose, and increase patient comfort and compliance.7 
Creating in situ implants has become a frequently used technique, by which the drug 
and a biodegradable polymer are dissolved in an organic solvent and administered 
by subcutaneous injection, generating a semi-solid depot. This drug delivery system 
is a good alternative to other implant devices for the following reasons: the process 
causes much less pain in comparison to implants, which require local surgery;   localized 
or systemic drug delivery can be maintained for months; ‘infusion-like’ plasma level 
time profiles minimize side effects. Other advantages include dose reduction to avoid 
peaks and valleys of drug concentration in blood, and enhanced patient compliance 
by reducing application frequency. In situ forming depot systems using polymers 
are relatively simple to produce and cost less than microspheres, which have to be 
washed and isolated.8
There are two different techniques for delivering in situ forming implants and in 
situ forming microparticles, depending on depot type. An in situ forming implant 
consists of a drug-containing biodegradable polymer solution in a biocompatible 
organic solvent. The solvent diffuses in the body’s aqueous environment, leading to International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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polymer precipitation and formation of an implant at the 
injection site. The most popular and biocompatible solvent 
used is N-methyl-2-pyrrolidone (NMP).9–13 Poly(d,l-lac-
tide-co-glycolide) (PLGA) is the most successfully used 
biodegradable and biocompatible polymer because of its 
two biodegradable hydrolysis products, lactic and glycolic 
acids (Figure 1).14
The properties of PLGA that affect drug release, includ-
ing its molecular weight (MW), lactide/glycolide ratio, and 
thermal properties, have been thoroughly investigated. Using 
lower MW PLGA increases the rates of polymer degradation 
and drug release. Decreasing the lactide content results in 
slower polymer degradation and slower drug release.15
Experimental design involves defining and investigating 
all factors thought to affect the outcome,16 and experiments 
are executed together or sequentially to optimize the variable 
parameters and define the optimum conditions. In situations 
involving numerous variables, a method called factorial 
design is used to discover the best combination of control 
factors to increase efficiency and reduce costs.17 However, 
this may not be possible in cases of high complexity.18 In the 
present study, we evaluated the parameters affecting the 
release rate of triamcinolone acetonide (TR) loaded on PLGA 
in the presence of other additives. Process parameters were 
optimized using the robust Taguchi method, which provides 
a comprehensive system for improving and optimizing drug 
release by considering equal contributions of variables.19 The 
resulting optimized formulation was characterized using 
scanning electron microscopy (SEM), X-ray diffraction 
(XRD), differential scanning calorimetry (DSC), and Fourier 
transform near infrared spectroscopy (FTNIR).
TR is a steroidal drug usually administered by the par-
enteral route (Figure 2). Its release from a biodegradable 
PLGA polymer can be evaluated by the two key parameters 
of burst release rate and release duration. These parameters 
are affected by drug loading, which is considered the main 
focus for in vivo burst release optimization.
Materials and methods
chemicals
The following chemicals were used as received from the 
suppliers: PLGA, Resomer® RG 504H (MW = 48,000 kDa) 
(Boehringer Ingelheim, Ingelheim, Germany), TR   (Farmabios, 
Gropello Cairopoli, Italy), NMP (Merck KGaA, Darmstadt, 
Germany), methanol (HPLC Gradient Grade, Merck KGaA), 
acetonitrile (HPLC Gradient Grade, Merck KGaA), NaOH 
(Merck KGaA), tetrahydrofurfuryl alcohol, polyethylene 
glycol ether (GL) (glycofurol, Merck KGaA), and hydroxy-
apatite (HA) nanoparticles (Sigma-Aldrich, Munich, 
Germany).
Methods and characterization
casting solution preparation
Homogeneous casting solutions (33% w/w) were prepared 
from PLGA in NMP. Varying amounts of drug were added 
and completely dissolved before introducing additives 
(Table 1). To study drug release patterns, experiments were 
carried out in glass vials type I (15 mL) (Schott Duran®, 
Mainz, Germany), because they possess the lowest avail-
able drug absorption properties. Vials were charged with the 
casting solutions, weighed immediately, and then filled with 
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Figure 2 structures of A) triamcinolone acetonide and B) polyethylene glycol ether.
Table 1 selected parameters and their levels for experimental 
design
Parameters Level
1 2 3
A) Tr% (w/w) 5 10 15
B) Nano hA% (w/w) 1 3 5
c) gL% (w/w) 1 3 5
Abbreviations: Tr, triamcinolone acetonide; hA, hydroxyapatite; gL, polyethylene 
glycol ether.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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10 mL degassed phosphate buffer (PB) (0.03 M, pH = 7.4) 
to minimize solvent exchange with air. All vials were incu-
bated at 37 ± 0.5°C. The entire receptor phase (10 mL) was 
withdrawn at predetermined intervals and replaced by the 
same amount of freshly prepared receptor medium.
release measurements
Formulation performance was evaluated by measuring TR 
release kinetics using a reverse phase high performance liquid 
chromatography (HPLC) method (C-18 column, 4.6 × 250 mm; 
NovaPak®; Waters, Milford, MA). The isocratic mobile phase 
consisted of a mixture of deionized water, acetonitrile, and 
methanol (62:33:5). Ultraviolet light absorbance was measured 
at 254 nm, and the column temperature was maintained at 25°C. 
Each experiment was performed in triplicate.
Formulation optimization
The experiments were designed using the Taguchi method. 
In order to determine the best formulations, three parameters, 
including TR, HA nanoparticles, and GL, as well as three 
levels for each parameter (Table 1) and a fractional facto-
rial design, namely, a standard L9 orthogonal array,20 were 
employed (Table 2). This orthogonal array was selected 
to reduce interaction among the parameters. Each row of 
the matrix represents one run. The sequence of these runs 
is randomized. As shown in Table 1, three different levels 
related to each parameter are represented as ‘1’, ‘2’, and ‘3’. 
QUALITEK-4 software (Nutek, Bloomfield Hills, MI) was 
used for experimental design and data analysis.21 Results are 
expressed as the average of the three analyses.
seM
Formulation surfaces were studied with a scanning elec-
tron microscope, VEGA 3 SB (TESCAN, as, Brno, Czech 
Republic). Gold-plated samples were examined at room 
temperature.
XrD
The XRD patterns of the formulations were measured 
using a PANalytical X-ray diffractometer (XPERT PRO, 
PW 3040/60 generator, PIXcel Detector and X’Pert Data 
  Collector software for automatic powder diffraction, v 2.2i; 
  PANalytical, Almelo, the Netherlands). The X-ray diffracto-
meter was operated with an anode current of 40 mA and an 
accelerating voltage of 40 kV . Samples were slightly pressed 
on an aluminium sample tray using a glass slide (75 × 25 mm) 
and exposed to CuKα radiation at diffraction angles (2q) from 
5° to 40° (step size, 0.02°; time per step, 40.01 seconds). 
X’Pert HighScore Plus (v 2.2d; PANalytical) software was 
used to locate the peaks in XRD diffractograms by detecting 
second derivative minima. Intensity maxima are expressed as 
Kα1 net peak height in counts at Kα1 position in degrees.
Dsc
A Perkin–Elmer DSC 7 (PerkinElmer, Skovlunde, Denmark) 
with Pyris software was used to determine the glass transition 
temperature (Tg). The sample (1.5–3.0 mg) was transferred 
to an aluminium pan in which a pinhole was punched in 
the pan lid, and the sides of the lid were crimped. A similar 
empty pan was used as reference. Samples were scanned 
from 10–70°C at a rate of 10°C/minute under nitrogen gas 
(20 mL/minute). Independent triplicate measurements are 
expressed as their means. The instrument was calibrated 
using an indium standard.
FTNIr
Infrared spectra were determined using a Bruker IR- 
spectrometer Tensor 37 (Bruker, Ettlingen, Germany) in 
single beam transmittance mode with optical probe. Each 
spectrum consisted of 32 scans collected in single beam at 
a resolution of 4 cm−1 at 25°C. Spectra were obtained on a 
straight baseline in the near infrared (NIR) region.
hot plate method
The hot plate test was performed in mice to assess the 
release response of triamcinolone. The hot plate test was 
performed by placing mice on an aluminum plate maintained 
at 51 ± 1°C. The latency to an analgesic response, identified 
as licking of either hind paw, or lifting of either hind paw 
from the heated surface, was measured.
Results and discussion
Data analysis
Figure 3 shows the release profiles of TR from different 
formulations of PLGA-based implants. In the present study, 
Table 2 L9 orthogonal array
Run # Parameter levels
A B C
1 1 1 1
2 1 2 2
3 1 3 3
4 2 1 2
5 2 2 3
6 2 3 1
7 3 1 3
8 3 2 1
9 3 3 2International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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to reduce the burst release associated with PLGA-based 
delivery systems formed in situ, we prepared nine different 
formulations incorporating TR and the additives described 
in Table 1. Experiments were executed based on the Taguchi 
design (Table 2).
Table 3 presents the release rates of a variety of formula-
tions containing different levels of additives. All additives, 
especially HA, improved release rates. HA naturally occurs 
in mineral form known as calcium apatite, whose formula, 
Ca5(PO4)3(OH), is usually written as Ca10(PO4)6(OH)2 to 
denote that the crystal unit cell includes 2 entities. HA is 
the hydroxyl-end member of the complex apatite group. The 
SEM image of HA (Figure 4) revealed that these non-sintered 
nanoparticles are nanocrystal clusters with equally spheri-
cal shape.22 Most of the drug-loaded formulations showed a 
biphasic release pattern (Figure 5) exhibiting an initial burst 
followed by sustained release.23,24 The high initial release 
may be due to the presence of free and weakly bound drug 
on the surface of carriers.
Prediction, optimization  
and characterization
To identify the main parameters’ influence on burst release, 
calculations were based on release data over 1.5 days 
 ( Figure 6). We used QUALITEK-4 software for this analysis 
(Table 3). In the Taguchi method, the main effect of control 
parameters indicates the trend of a parameter’s influence. 
The key effects were calculated using average release. 
The results indicate the drug loading effect on the release 
profile (Figure 7). Another technique for optimization of 
the results suggested by the Taguchi method is analysis of 
variance (ANOVA). Table 4 presents the analysis of variance 
(ANOVA) values, which indicate the relative influence of 
factor and interaction to the variation of results. ANOVA is 
similar to regression analysis, which is used to investigate 
and determine the relationship between a response variable 
and one or more independent variables.21 Furthermore, Bese 
et al25 state that optimal combination of process parameters 
can be predicted from the performance characteristics and 
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Figure 3 Triamcinolone acetonide release kinetics in poly(d,l-lactide-co-glycolide) 
in phosphate buffer.
Table 3 cumulative release after 1.5 days
Run # % response Average (%) SD
1 2 3
1 4.5 4.0 4.1 4.2 0.3
2 3.9 4.1 4.7 4.2 0.4
3 4.7 4.6 4.2 4.5 0.3
4 2.0 2.3 2.0 2.1 0.2
5 2.2 2.3 2.2 2.2 0.1
6 2.3 2.5 2.4 2.4 0.1
7 1.5 1.6 1.6 1.5 0.1
8 1.4 1.5 1.3 1.4 0.1
9 1.2 1.5 1.3 1.3 0.2
Figure 4 hydroxyapatite nanoparticles.
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Figure 5 cumulative triamcinolone acetonide release kinetics in poly(d,l-lactide-
co-glycolide)-hydroxyapatite in phosphate buffer.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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ANOVA analyses. The contributions of each parameter to 
burst release optimization and expected optimum condition 
are listed in Table 5. According to the Taguchi method, TR 
had the highest contribution to the decrease of burst release. 
The highest percentage for control parameters was obtained 
with the following composition: TR (15%), HA (1%), and 
GL (3%).
At optimal conditions, burst release decreased to 1.3%. 
The drug contents in PLGA and PLGA-HA based formula-
tions were 5%, 10%, and 15% (drug/PLGA). These starting 
values of TR for PLGA and PLGA-HA formulations were 
taken as the 100% starting values of the released drug. TR 
release from PLGA (Figure 3) and PLGA-HA (Figure 6) was 
conducted in PB (pH 7.4). As can be seen, the release profiles 
of the two formulations are different (Figures 3 and 6). The 
PLGA release profile is characterized by a biphasic drug 
release typically exhibited by biodegradable polymers: an 
initial burst followed by a sustained release. However, 
PLGA-HA displayed a triphasic drug release. During the first 
1.5 days, a small ‘burst’ was observed for both PLGA (8%) 
and PLGA-HA (4.5%) based on the total amount of loaded 
drug. The initial burst was caused by the drug’s rapid release 
near the surface. The second plateau phase for PLGA-HA 
lasted around 20 days with a low dose of TR released. The 
plateau phase was followed by a third stage with decreasing 
drug release lasting for over 100 days. A gradually increased 
release during the first 20 days was followed by a slow release 
at a nearly constant rate of 0.05% per day for PLGA-HA. 
The cumulative drug release profile of TR (15%) from 
PLGA was similar to that of PLGA-HA. These release rates 
were 1.5 and 2 times that of 10% and 5% TR, respectively 
  (Figures 3 and 6). These results show that at 15% TR, its 
release is independent of additive. In contrast, HA controlled 
the release rate of 5% and 10% TR.
Triphasic drug release follows the following stages: ini-
tial burst, followed by drug diffusion, with polymer degrada-
tion occurring at the third phase. The second phase, which 
continues for about 20 days, is governed by swelling of the 
PLGA in situ forming implant. TR is released slowly from 
the in situ gel, and is replaced by water. The precipitation of 
PLGA follows a biphasic mechanism. After injection, a thin 
PLGA membrane is immediately formed at the injection 
site. Dissolved NMP and TR diffused through this polymer 
shell into the aqueous environment, and water diffused into 
the polymer, simultaneously. As hardening of the PLGA 
membrane increases due to further polymer precipitation, the 
diffusion distances are increased. According to the Einstein–
Smoluchowski equation (1), where D, d, and t are the diffu-
sion coefficient, distance and time, respectively, as diffusion 
distances inside the implant are increased, the diffusion times 
for NMP outside, and water inside, are increased.26,27 This 
is represented by the   following equation:
  D
d
t
t
d
D
=→ =
22
22
  (1)
During the formation of implants of PLGA and 
PLGA-HA in situ in PB, the pH decreased to approximately 
5 and 6, respectively. In the presence of HA, the pH decreased 
more slowly (Figure 8). Lactic and glycolic acids are two 
products that are generated by PLGA biodegradation and 
cause tissue inflammation at the injection site. Compared to 
PLGA, PLGA-HA demonstrated significant buffer capacity. 
This anti-inflammatory property, which was expected from 
this formulation, is in accordance with other studies.28,29 
After 20 days, while the PLGA formulation was extensively 
degraded (Figure 9A), PLGA-HA was only partially disrupted 
(Figure 9B). Slower degradation of PLGA-HA is due to the 
presence of HA. Meanwhile, this additive caused a low burst 
and controlled the overall rate of drug release as shown in 
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Figure  6  cumulative  Tr  release  kinetics  in  poly(d,l-lactide-co-glycolide)-
hydroxyapatite in phosphate buffer (after 1.5 days).
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Figure 5. HA as a bisphosphonated and chelating component 
can be encapsulated into the PLGA matrix. This non-mutually 
exclusive hypothesis can be proposed as a reason for the slow 
degradation of PLGA-HA. In addition, HA degradation in pH 
, 4.2 has been investigated previously.29 This biodegradation 
releases Ca2+ and the result is pH buffering capacity. This can 
be combined with the anti-inflammatory properties of TR for 
better control of inflammation due to PLGA hydrolysis at the 
injection site, using this optimized formulation.
Glycofurol is a water-miscible solvent which is used 
in the preparation of parenteral pharmaceutical dosage 
forms and with PLGA for in situ gel forming.7,30 This non-
toxic solvent enhances the solubility and permeability of 
water-insoluble drugs.31,32 XRD data evaluation leads to 
the conclusion that TR forms a crystalline structure, which 
becomes somewhat degraded in the PLGA matrix. This 
structure was converted to amorphous TR in the presence 
of 3% GL. This transition results from hydrogen bonding 
between TR and GL (Figure 10). The solubility of amor-
phous TR in intrinsically amorphous PLGA is greater than 
that of crystalline TR. This increases the density of the 
membrane structure (Figure 11A) and leads to lower burst 
release. In the absence of GL, upon phase inversion, TR 
remains crystalline, and some of these crystals escape from 
the membrane   (Figure 11B) causing a burst release. GL 
increases the solubility of TR, increasing its bioavailability, 
consistent with studies by Bakarat.33
The structure of polymeric materials can be identified by 
combinations and overtone vibration of X–H bonds using 
near infrared (NIR) absorption. Hydrogen bonds in O–H 
groups give rise to sharp peaks in infrared (IR)   spectroscopy.34 
The Fourier Transform infrared spectroscopy (FTIR) spectrum 
revealed interaction between PLGA and amorphous TR, 
which decreases burst release (Figure 12).
DSC analysis of TR shows endothermic peaks in the 
242–280°C range, which is characteristic of polymorph A 
and B.35,36 The glass transition temperature (Tg) of PLGA in 
situ forming gels, including TR (15%) and GL (3%), was 
49.8°C. This is also evidence for the transition of TR from a 
crystalline to an amorphous form in the presence of GL, and 
the existence of elastic properties in the PLGA membrane.31 
Solubilization by GL causes this, decreases the burst release, 
and makes a dense structure of the PLGA implant.
In vivo studies
Drug release through PLGA has been studied in detail.37–41 
The purpose of the present study is to systematically incor-
porate specific excipients into TR-loaded PLGA in situ gel 
formulations in order to evaluate the burst effect in vivo. 
The hot-plate test was administered to mice to assess their 
response to TR release. The latency of an analgesic response 
was identified as either licking or lifting of a hind paw 
from the heated surface. A preliminary study of the time 
course of TR’s analgesic activity in mice was performed to 
  determine the time to peak analgesic activity and effective 
dose 50 (ED50). Eight groups of mice (five mice per group), 
Table 4 ANOVA for cumulative release after 1.5 days
Parameters DOF Sum of squares Variance F-ratio Pure sum Percent (%)
A) Tr% (w/w) 2 39.6 19.8 450.0 39.5 96.9
B) Nano hA% (w/w) 2 0.1 0.0 1.0 0.0 0.0
c) gL% (w/w) 2 0.2 0.1 2.3 0.1 0.3
Other/error 20 0.9 0.0 2.8
Total 26 40.8 100.0
Abbreviations: Tr, triamcinolone acetonide; hA, hydroxyapatite nanoparticles; gL, polyethylene glycol ether.
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Figure 8 effects on ph of triamcinolone acetonide (5%) with PLgA or PLgA-hA.
Abbreviations: PgLA, poly(d,l-lactide-co-glycolide); PgLA-hA, poly(d,l-lactide-
co-glycolide) with hydroxyapatite.
Table 5 Optimum conditions for the burst release reduction
Parameter Level description Level Contribution
A) Tr% (w/w) 15 3 1.230
B) Nano hA% (w/w) 1 1 0.041
c) gL% (w/w) 3 2 0.108
Total contribution from all parameters: 1.380
current grand average of performance: 2.662
expected result at optimum condition: 1.283
Abbreviations: Tr, triamcinolone acetonide; hA, hydroxyapatite nanoparticles; 
gL, polyethylene glycol ether.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 9 seM image of membranes after immersion in phosphate buffer for 20 days: 
A)  poly(d,l-lactide-co-glycolide)  and  B)  PgLA-hA:  poly(d,l-lactide-co-glycolide) 
with hydroxyapatite.
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Figure 10 Diffractograms of A) triamcinolone acetonide B) PLgA and triamcinolone 
acetonide (15%), C) PLgA and triamcinolone acetonide (15%) and polyethylene 
glycol ether (3%).
Abbreviation: PLgA, poly(D,L-lactide-co-glycolide).
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Figure 11 scanning electron microgram of poly(d,l-lactide-co-glycolide) membranes: 
A) 3% and B) 0% polyethylene glycol ether.
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Figure 12 Fourier transform near infrared spectra of poly(d,l-lactide-co-glycolide) 
membranes in the presence of A) 0%, B) 1%, and C) 3% polyethylene glycol ether.
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Figure 13 hot-plate response of mice (n = 5) administered triamcinolone acetonide.
designated as group A and B, were selected. TR (0.01 mg/kg, 
0.05 mg/kg, 0.1 mg/kg and 0.5 mg/kg) with and without 
PLGA was injected intramuscularly into members of group 
A and B, respectively. Latency time was measured at 30, 
60, 90, 120, 150, and 180 minutes after administration. 
Injections without PLGA caused a significant increase in 
reaction times (Figure 13), while PLGA injections caused 
only a small change (Figure 14). The increase in reaction 
time was dose-dependent and differed significantly among 
the groups of mice receiving different TR doses. The data 
demonstrate that the burst release of TR from the PLGA 
matrix was very low and that a sustained release of the drug 
was achieved. Overall evaluation of these results shows that 
the data are quite comparable to those acquired in vitro. The 
burst release was decreased and the TR concentration had 
the greatest effect on control of the burst effect. Thus, we 
conclude that PLGA injected into the body acts as a depot 
for the sustained release of TR.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
832
Koocheki et al
Conclusion
We applied the Taguchi method to predict and optimize in 
situ gel formulation of TR and PLGA polymer in the presence 
of HA nanoparticles and GL additives. Drug release followed 
a linear pattern throughout dissolution after 1.5 days using 
PLGA and PLGA-HA. The amount of TR released after 
1.5 days, irrespective of the type of formulation, was less than 
8%. Different formulations were achieved using the Taguchi 
method and we found that burst release decreased to 1.3% 
using TR (15%), HA (1%), and GL (3%) formulations.
Analysis of in vitro and in vivo studies showed that TR 
concentration contributes most significantly to the control 
of burst release. The study of drug release continued over 
125 days in vitro. This prolonged delivery period will enable 
decreased drug dosage and possibly reduce the TR’s undesir-
able side effects. The PLGA-HA combination exhibited sig-
nificant buffering capacity that prevented tissue inflammation 
at the injection site, which is the result of acidic degradation 
products of the PLGA membrane.
The structure of TR changed from crystalline to amorphous 
in the presence of GL, which increases TR’s solubility in 
PLGA, resulting in low burst release. The drug release pat-
tern observed during this study can be considered the result of 
developing a novel drug delivery system based on optimizing 
water-insoluble drug release, decreasing tissue inflammation 
and minimizing burst release. This system promises to be useful 
for routine drug delivery research particularly in regard to in situ 
gel formulation and burst control for high potency drugs.
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